Following is the latest announcement released on PR Newswire this morning. We are excited to announce that we were awarded another patent by the USPTO, this time for our "stability timer" feature in our evo.is app. This customizable feature lets all parties focus on the time critical nature of a shipment.
Savsu continues to innovate on both the hardware and software sides of the business. It's an imperfect analogy but, our evo system is a bit like the manned space program: our hardware is the"space capsule" and our evo.is software is "mission control". You needs both working in harmony to bring the precious cargo safely home. Look for more announcements about hardware and software innovations in the coming months.
6 Additional Pending Patent Applications Submitted for evo Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application
ALBUQUERQUE, N.M., July 31, 2018 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance of patent number 10,018,614 B2, titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials". The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions (NASDAQ:BLFS).
SAVSU has been granted 3 patents and has 6 other pending patent applications related to novel innovations incorporated into current, or to be incorporated into future, precision thermal shipping containers under the evo brand, including models that precisely maintain biologic payload temperature stability across the entire shipping continuum including -196°C using liquid nitrogen dry vapor shippers, -80°C using dry ice, and 2° - 8°C and controlled room temperature (CRT) using conditioned phase change insulating materials. These patent applications also include claims related to the evo.is Cold Chain Software as a Service (SaaS) live cell visibility platform.
Bruce McCormick, commented, "This patent grant further validates our mission to offer truly innovative biopreservation tools for regenerative medicine, with a focused and intentional goal to improve cold chain logistics of cell and gene therapies. We believe the advanced and innovative evo hardware and software technologies will have tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive biologic medicines."